Can a patient sign electronically?

Yes. Electronic signatures are legally binding under the ESIGN Act (15 U.S.C. §7001) and UETA where adopted, provided the signing shows intent, consent, attribution, and the record can be retained and reproduced. For consumer-facing health records, follow ESIGN consumer-disclosure requirements.

Is a notary required for this agreement?

Typically no; most clinical consents and treatment agreements do not require notarization. Check state law or payer requirements if a notarized acknowledgement is requested. If a notary is required, Remote Online Notarization (RON) rules vary by state and may impose identity-proofing and recording obligations.

How does HIPAA affect electronic signing?

When the agreement contains PHI, the covered entity must protect privacy and security per HIPAA. Use a vendor that will sign a Business Associate Agreement and supports technical safeguards; retain records consistent with 45 CFR §164.530(j).

How long should signed agreements be retained?

Follow federal and state retention rules: retain health records including consents for six years under HIPAA (45 CFR §164.530(j)) and keep tax-related documentation per IRC §6501(a). State regulators may require longer retention for clinical records.

Who must sign the agreement?

The patient and the prescriber should sign. If the patient lacks capacity, a legally authorized representative or guardian should sign and documentation of authority should be retained. Include witness or notary if state or institutional policy requires it.

How can the agreement be revised or revoked?

Amendments should be documented in writing, signed by the parties, and appended to the medical record. To revoke or terminate treatment, document clinical rationale, communicate changes to the patient, and follow local prescribing and transfer-of-care protocols.

Electronic Signature
Templates
Legal
Pain Medicine Treatment Agreement

Pain Medicine Treatment Agreement

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

PAIN MEDICINE TREATMENT AGREEMENT

This Pain Medicine Treatment Agreement (Agreement) is entered into between Patient Name: (Patient) and Prescribing Clinician: of Practice/Clinic: effective as of Date:

RECITALS

WHEREAS, Patient suffers from chronic pain for which the parties seek to use controlled prescription medications or other pain management modalities to reduce pain and improve function; and

WHEREAS, Prescribing Clinician is licensed and qualified to prescribe controlled substances and to monitor the use of such medications; and

WHEREAS, the parties desire to set forth the terms, conditions, responsibilities, monitoring, and limitations applicable to the prescription and use of pain medicine for Patient.

NOW, THEREFORE, in consideration of the mutual promises contained herein, the parties agree as follows.

1. TREATMENT PLAN

1.1 Objective. The primary goals of treatment are to reduce pain, increase physical function, and improve quality of life. Patient acknowledges that complete elimination of pain may not be achievable and that treatment focuses on measurable functional improvement.

1.2 Authorized Medications. The medications, dosages, and frequency initially authorized under this Agreement are listed below. Any changes must be documented by the Prescribing Clinician.

Medication(s) and Dosage(s): Treatment Goals (functional objectives):

2. PATIENT OBLIGATIONS

2.1 Use and Storage. Patient shall take medications only as prescribed, shall store them securely to prevent loss or theft, and shall not permit others to use the medications. Lost, damaged, or stolen medication will not be replaced except in documented emergencies and at clinician discretion.

2.2 One Prescriber and One Pharmacy. Patient agrees to receive controlled substance prescriptions only from the Prescribing Clinician and to designate a single pharmacy for all controlled medication prescriptions.

Pharmacy Name and Address: Emergency Contact (Name and Phone):

2.3 Compliance. Patient must comply with requested monitoring including urine drug screens, pill counts, and other reasonable measures. Failure to comply or evidence of diversion, tampering, or unauthorized use may result in tapering or termination of controlled medication prescriptions and transfer of care.

3. PRESCRIBER OBLIGATIONS

3.1 Evaluation and Monitoring. Prescribing Clinician will evaluate Patient’s pain, function, and risks; will document treatment rationale; and will periodically review the medication regimen and monitoring results. Clinician will attempt to coordinate care and discuss alternatives where appropriate.

3.2 Controlled Substances Review. Prescribing Clinician will check applicable prescription monitoring records and may consult other treating clinicians as necessary to ensure safe prescribing practices.

4. MONITORING, TESTING, AND RECORDS

4.1 Urine Drug Screening and Testing. Patient consents to periodic urine drug screening and other testing as deemed clinically appropriate. Refusal to submit to testing without valid cause will be treated as a violation of this Agreement.

4.2 Pill Counts and Medication Reconciliation. Patient agrees to bring medication containers to appointments for pill counts and reconciliation. Failure to present medications on request may result in cessation of prescribing.

Consent to Urine Drug Screening:

I consent to urine drug screening and related testing as required by the Prescribing Clinician.

Consent to Pill Counts:

I agree to present medications for pill counts upon request.

5. PRESCRIBING, REFILLS, AND EARLY REFILLS

5.1 Refills. Refills will be provided only during scheduled visits unless otherwise authorized. Requests for refills outside regular business hours may be denied. Lost or stolen medications are not routinely replaced.

5.2 Early Refills. Early refill requests will be assessed for legitimate clinical need. Consistent early refill requests may indicate misuse and may lead to termination of controlled substance therapy.

6. RISKS, SIDE EFFECTS, AND ALTERNATIVES

6.1 Risks and Side Effects. Patient acknowledges that use of opioid and other controlled medications carries risks including addiction, overdose, respiratory depression, sedation, cognitive impairment, and withdrawal. Patient has had the opportunity to discuss these risks and alternatives with the Prescribing Clinician.

6.2 Alternatives. Non-opioid therapies, non-pharmacologic treatments, interventional procedures, and behavioral strategies may be recommended and used alone or in combination with medication therapy.

7. TERMINATION OF TREATMENT

7.1 Grounds for Termination. The Prescribing Clinician may taper or discontinue controlled substance prescriptions and/or terminate the therapeutic relationship for noncompliance, evidence of diversion, illicit drug use, repeated early refill requests, refusal to undergo monitoring, or other violations of this Agreement.

7.2 Tapering. If medications are discontinued, prescriber will consider an appropriate taper when clinically feasible. Sudden cessation may present medical risk and should be avoided when possible.

8. CONFIDENTIALITY AND RECORDS

8.1 Medical Records. All clinical information regarding pain management, prescriptions, and monitoring will be recorded in the medical record. Records will be maintained in accordance with applicable law and professional standards.

8.2 Release of Information. Patient authorizes the Prescribing Clinician to obtain and release relevant medical and prescription monitoring records to coordinate care and to comply with legal reporting obligations.

9. NOTICES

9.1 Notices to Patient. The Prescribing Clinician may provide notices regarding this Agreement, appointments, monitoring, or changes to therapy in writing or by telephone to contact information on file.

Patient Address: Patient Phone:

10. MISCELLANEOUS LEGAL PROVISIONS

10.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the state in which the Prescribing Clinician is licensed, without regard to conflict of laws principles.

10.2 Entire Agreement. This Agreement constitutes the entire understanding between the parties concerning pain medication management and supersedes prior oral or written statements on the subject.

10.3 Severability. If any provision of this Agreement is held invalid or unenforceable, the remainder of the Agreement shall remain in full force and effect.

10.4 Amendments. Any amendment to this Agreement must be in writing and signed by both parties. Waiver of any provision must be in writing to be effective.

10.5 Waiver. Failure by either party to enforce any right under this Agreement shall not constitute a waiver of future enforcement of that or any other right.

10.6 Counterparts and Electronic Signatures. This Agreement may be signed in counterparts and signatures transmitted electronically or by facsimile shall be effective as originals.

11. ACKNOWLEDGMENTS AND CERTIFICATIONS

By signing below, Patient acknowledges that Patient has read this Agreement, has had the opportunity to ask questions, understands the risks and benefits of prescribed medications, agrees to comply with the terms set forth herein, and consents to the monitoring and record-sharing provisions described in this Agreement.

Patient Date of Birth: Clinician License Number:

Patient Name:

By:

Date:

Provider Name:

By:

Date:

What the Pain Medicine Treatment Agreement Is

A Pain Medicine Treatment Agreement documents the informed consent and mutual obligations between a patient and a prescriber when controlled or high-risk pain medications are prescribed. It defines treatment goals, monitoring expectations, refill rules, and responses to noncompliance, and it records patient acknowledgement of risks and alternatives. The agreement becomes part of the medical record, supports clinical decision-making, and creates a documented protocol for urine drug testing, prescription limits, PDMP checks, and care coordination with pharmacies and other clinicians to meet payer and regulatory expectations.

Why a Clear Agreement Matters for Providers and Patients

A properly drafted Pain Medicine Treatment Agreement clarifies expectations, reduces clinical and legal risk, documents informed consent, and standardizes monitoring and refill procedures to support regulatory compliance and continuity of care.

Who Typically Uses This Agreement

Clinicians and care teams use Pain Medicine Treatment Agreements to document shared responsibilities, while patients acknowledge risks, monitoring, and treatment expectations.

Primary care physicians and pain specialists managing long-term opioid therapy.
Clinic nurses, care coordinators, and pharmacists involved in monitoring and refills.
Patients receiving controlled substances who must consent to monitoring and treatment limits.

The agreement connects clinical practice with administrative workflows and payer or regulatory review, creating a single reference for monitoring, refills, and escalation steps.

Roles Involved in the Agreement

Clinician

A treating clinician (physician, nurse practitioner, or physician assistant) who prescribes pain medication and documents the treatment plan. The clinician explains risks and monitoring (urine drug tests, pill counts), documents informed consent, and enforces refill and compliance policies consistent with state law.

Patient

The patient agrees to follow the treatment plan, report side effects, attend scheduled monitoring, and accept limits on early refills or dose increases. Refusal to comply may result in therapy modification or referral, as documented in the medical record.

Core Sections to Include in the Agreement

A professional Pain Medicine Treatment Agreement should be structured to set goals, detail the medication plan, define monitoring, list patient responsibilities, specify refill rules, and explain consequences for noncompliance.

Treatment Goals

Describe functional objectives, pain reduction targets, and expected timeframe. Clear goals help evaluate effectiveness and justify continuing, tapering, or changing medications during follow-up visits regularly.

Medication Plan

List current medications, doses, maximum daily amounts, permitted prescribers, and refill policies. Include start and review dates to track changes and prevent duplicate controlled-substance prescribing.

Monitoring

Specify urine drug screening frequency, pill counts, random testing, PDMP checks, and documentation requirements. State who orders tests, how results affect treatment, and how samples are handled for confidentiality.

Patient Responsibilities

Require adherence to dosing, secure storage, no sharing of medications, prompt reporting of adverse events, and early communication about lost or stolen prescriptions. Noncompliance may trigger tapering or discontinuation.

Refill Rules

Set refill windows, requirement for in-person or telehealth visits before refills, limitations on early refills, and procedures for acute pain exceptions. Clarify responsibility for lost or destroyed medication requests.

Consequences

Outline steps for noncompliance: additional counseling, increased monitoring, tapering, referral to addiction services, or termination of opioid therapy. Describe urgent actions for diversion or threats to patient or public safety.

Step-by-Step: Completing and Filing the Agreement

Follow these steps to complete and integrate a Pain Medicine Treatment Agreement into the medical record.

01

Prepare Document: Use clinic template and customize patient details.
02

Review Risks: Discuss risks, alternatives, and expectations with the patient.
03

Sign & Date: Both patient and prescriber sign and date the form.
04

File Record: Scan or add signed form to the electronic medical record.

How the Agreement Moves Through Clinical Workflows

This summary shows how the agreement moves from creation to storage, including monitoring triggers and refill workflows.

Create Template: Customize clinic's standard agreement with practice policies.
Obtain Consent: Discuss and document informed consent before initiating therapy.
Monitor Compliance: Schedule tests and reviews per the monitoring plan.
Update Plan: Revise medications or discontinue therapy based on evidence.

Digital Workflow Settings for the Agreement

Configure your clinic's digital workflow so the agreement is auto-populated, routed, and archived consistently across systems.

Field	Configuration
Patient Demographics	Map from EHR fields
Provider Signature	Require authenticated signer
Monitoring Reminders	Automated alerts for tests
Archive Location	Save to EMR legal chart

Platform and Integration Considerations

Use an eSignature-enabled platform that supports secure storage, audit trails, and HIPAA protections when handling Pain Medicine Treatment Agreements.

File formats: PDF, DOCX supported
Integrations: EHR, pharmacy, PDMP systems
Authentication: Email, SMS, or advanced MFA

Security and Compliance Basics

Encryption in transit: TLS 1.2/1.3 supported

Encryption at rest: AES-256 encryption

HIPAA compliance: BAA required for PHI

Audit trail: Timestamped signer events

21 CFR Part 11: Audit-ready signatures

Access controls: Role-based permissions

Common Preparation Pitfalls to Avoid

Incomplete patient information or unsigned agreements can delay treatment, trigger payer denials, and complicate audits or licensing board reviews.
Failing to document monitoring results—such as missed urine drug screens—undermines clinical decisions and increases regulatory risk during investigations.
Using noncompliant electronic platforms without a BAA or proper authentication can expose protected health information and breach HIPAA obligations.
Vague or open-ended refill policies invite disputes and may lead to inconsistent prescribing or medication diversion among patients.

Penalties and Risks of Incomplete or Incorrect Agreements

Improper Prescribing: Civil and administrative liability

Patient Harm: Medical malpractice risk

Regulatory Fines: State board enforcement

Criminal Charges: Possible criminal prosecution

Insurance Denial: Coverage disputes possible

Recordkeeping Failures: Audit penalties, payer denial

Key Monitoring and Documentation Timelines

Key timelines for monitoring, review, and documentation help ensure clinical safety and regulatory compliance in busy practices.

Initial visit and consent signature:

Document signed before first controlled prescription

Scheduled follow-up review frequency:

Every 30–90 days depending on risk

Urine drug screen schedule:

At baseline and periodically per plan

PDMP review cadence:

Check at initiation and periodically

Refill authorization window:

Require visit before refill within two weeks

Milestones from Agreement to Ongoing Review

Sequential milestones from consent to long-term review clarify responsibilities and trigger monitoring actions in workflows.

01

Consent Signed

Agreement executed and placed in record.

02

Baseline Testing

Urine and labs ordered before therapy start.

03

Periodic Review

Scheduled clinical evaluation and PDMP review.

04

Renewal Decision

Adjust, taper, or continue plan based on evidence.

Pricing and Feature Comparison for eSignature Solutions

Compare common eSignature plan starting prices and practical features relevant to Pain Medicine Treatment Agreements and HIPAA workflows.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Free trial available	Free trial available	Free trial available	Free trial available
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Frequently Asked Questions

Answers to common practical and legal questions about execution, eSigning, notarization, and recordkeeping for Pain Medicine Treatment Agreements.

Need help? Contact support

Can a patient sign electronically?
Yes. Electronic signatures are legally binding under the ESIGN Act (15 U.S.C. §7001) and UETA where adopted, provided the signing shows intent, consent, attribution, and the record can be retained and reproduced. For consumer-facing health records, follow ESIGN consumer-disclosure requirements.
Is a notary required for this agreement?
Typically no; most clinical consents and treatment agreements do not require notarization. Check state law or payer requirements if a notarized acknowledgement is requested. If a notary is required, Remote Online Notarization (RON) rules vary by state and may impose identity-proofing and recording obligations.
How does HIPAA affect electronic signing?
When the agreement contains PHI, the covered entity must protect privacy and security per HIPAA. Use a vendor that will sign a Business Associate Agreement and supports technical safeguards; retain records consistent with 45 CFR §164.530(j).
How long should signed agreements be retained?
Follow federal and state retention rules: retain health records including consents for six years under HIPAA (45 CFR §164.530(j)) and keep tax-related documentation per IRC §6501(a). State regulators may require longer retention for clinical records.
Who must sign the agreement?
The patient and the prescriber should sign. If the patient lacks capacity, a legally authorized representative or guardian should sign and documentation of authority should be retained. Include witness or notary if state or institutional policy requires it.
How can the agreement be revised or revoked?
Amendments should be documented in writing, signed by the parties, and appended to the medical record. To revoke or terminate treatment, document clinical rationale, communicate changes to the patient, and follow local prescribing and transfer-of-care protocols.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now